Carbon Footprint of Decentralized Clinical Trials
Data FAIRy Bioassay Annotation
Global Substance Registration System
IDMP Ontology
In Vitro NAM Data Standards
In Vitro Pharmacology
Large Language Models in Life Sciences
Pharma General Ontology
Social Media Real World Evidence
Current Projects
Delivered Projects
AI / ML
CSCS
Data Governance
FAIR
Lab of the Future
Microbiome-Mediated Drug Metabolism Database
Quantum Computing
UXLS
Current Communities
Delivered Communities
Delivered Projects and Communities
New Ideas
Username or Email Address
Password
Remember Me
News Article
A catalyst to unleash the potential of AI and accelerate data-driven decisions with industry standards
Regulatory bodies worldwide have initiated patient-focused drug development (PFDD) initiatives to foster a more systematic involvement of patients in the drug development process and to ensure that outcomes measured in clinical trials are truly relevant to patients and represent significant improvements to their quality of life.
Drug Discovery World : Publication on the Pistoia Alliance Blockchain Informed Consent
The DataFAIRY model we have developed will not only reduce the time bench scientists spend searching for assay information.
With the capacity to produce and record data electronically, Scientific research and the data associated with it have grown at an unprecedented rate
JUMP-Cell Painting Consortium created a new data-driven approach to drug discovery based on cellular imaging, image analysis, and high dimensional data analytics
The life sciences and healthcare industries should restructure around patient centricity, according to global not-for-profit the Pistoia Alliance.
Best Practices Guides
Recently, artificial intelligence (AI) and machine learning (ML) technologies in the biotechnology and pharmaceutical industries moved beyond experiments conducted by a few dedicated specialists and entered the industry mainstream. With this transition comes the need to formalize and publish the lessons learned by early adopters.
Due to their binding versatility, antibodies are currently the largest class of biotherapeutics, with five monoclonal antibodies ranked in the top 10 blockbuster drugs. Computational advances in protein modelling and design can have a tangible impact on antibody-based therapeutic development.